Literature DB >> 15328111

Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells.

Yoshifumi Imamura1, Katsunori Yanagihara, Yohei Mizuta, Masafumi Seki, Hideaki Ohno, Yasuhito Higashiyama, Yoshitsugu Miyazaki, Kazuhiro Tsukamoto, Yoichi Hirakata, Kazunori Tomono, Jun-ichi Kadota, Shigeru Kohno.   

Abstract

The features of chronic airway diseases, including chronic bronchitis, cystic fibrosis, bronchiectasis, and diffuse panbronchiolitis, include chronic bacterial infection and airway obstruction by mucus. Pseudomonas aeruginosa is one of the most common pathogens in chronic lung infection, and quorum-sensing systems contribute to the pathogenesis of this disease. The quorum-sensing signal molecule [N-(3-oxododecanoyl) homoserine lactone (3O-C(12)-HSL)] not only regulates bacterial virulence but also is associated with the immune response. In this study, we investigated whether 3O-C(12)-HSL could stimulate the production of a major mucin core protein, MUC5AC. The effect of a macrolide on MUC5AC production was also studied. 3O-C(12)-HSL induced NCI-H292 cells to express MUC5AC at both the mRNA and the protein levels in time- and dose-dependent manners. A 15-membered macrolide, azithromycin, inhibited MUC5AC production that was activated by 3O-C(12)-HSL. 3O-C(12)-HSL induced extracellular signal-regulated kinase (ERK) 1/2 and I-kappa B phosphorylation in cells, and this induction was suppressed by azithromycin. 3O-C(12)-HSL-induced MUC5AC production was blocked by the ERK pathway inhibitor PD98059. Our findings suggest that the P. aeruginosa autoinducer 3O-C(12)-HSL contributes to excessive mucin production in chronic bacterial infection. Azithromycin seems to reduce this mucin production by interfering with intracellular signal transduction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15328111      PMCID: PMC514791          DOI: 10.1128/AAC.48.9.3457-3461.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions.

Authors:  J R Davies; N Svitacheva; L Lannefors; R Kornfält; I Carlstedt
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Human respiratory mucus.

Authors:  M Kaliner; J H Shelhamer; B Borson; J Nadel; C Patow; Z Marom
Journal:  Am Rev Respir Dis       Date:  1986-09

3.  Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro.

Authors:  S K Goswami; S Kivity; Z Marom
Journal:  Am Rev Respir Dis       Date:  1990-01

Review 4.  Epithelial mucin genes.

Authors:  S J Gendler; A P Spicer
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

5.  A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa.

Authors:  J P Pearson; L Passador; B H Iglewski; E P Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors:  Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

7.  Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes.

Authors:  J P Pearson; K M Gray; L Passador; K D Tucker; A Eberhard; B H Iglewski; E P Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

Review 8.  Mucin in disease. Modification of mucin gene expression in airway disease.

Authors:  B Jany; C B Basbaum
Journal:  Am Rev Respir Dis       Date:  1991-09

9.  Interleukin-1beta induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 cells.

Authors:  Yong-Dae Kim; Eun-Jin Kwon; Dae-Won Park; Si-Youn Song; Seok-Keun Yoon; Suk-Hwan Baek
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

10.  LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression.

Authors:  M J Gambello; S Kaye; B H Iglewski
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.609

View more
  27 in total

Review 1.  The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

2.  Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing.

Authors:  C A Martin; A D Hoven; A M Cook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-06       Impact factor: 3.267

3.  N-acyl-homoserine lactone confers resistance toward biotrophic and hemibiotrophic pathogens via altered activation of AtMPK6.

Authors:  Adam Schikora; Sebastian T Schenk; Elke Stein; Alexandra Molitor; Alga Zuccaro; Karl-Heinz Kogel
Journal:  Plant Physiol       Date:  2011-09-22       Impact factor: 8.340

4.  Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression.

Authors:  Masaharu Shinkai; Jun Tamaoki; Hideo Kobayashi; Soichiro Kanoh; Kazuo Motoyoshi; Tim Kute; Bruce K Rubin
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 5.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

6.  Pseudomonas aeruginosa Homoserine lactone activates store-operated cAMP and cystic fibrosis transmembrane regulator-dependent Cl- secretion by human airway epithelia.

Authors:  Christian Schwarzer; Steven Wong; James Shi; Elizabeth Matthes; Beate Illek; Juan P Ianowski; Ryan J Arant; Ehud Isacoff; Horia Vais; J Kevin Foskett; Isabella Maiellaro; Aldebaran M Hofer; Terry E Machen
Journal:  J Biol Chem       Date:  2010-08-25       Impact factor: 5.157

Review 7.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

8.  Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells.

Authors:  Kentaro Nagaoka; Katsunori Yanagihara; Yosuke Harada; Koichi Yamada; Yohei Migiyama; Yoshitomo Morinaga; Hiroo Hasegawa; Koichi Izumikawa; Hiroshi Kakeya; Masaharu Nishimura; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

9.  Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia.

Authors:  Carla Maria P Ribeiro; Harry Hurd; Yichao Wu; Mary E B Martino; Lisa Jones; Brian Brighton; Richard C Boucher; Wanda K O'Neal
Journal:  PLoS One       Date:  2009-06-05       Impact factor: 3.240

Review 10.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.